Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant

Fragile X Syndrome: An Update on Developing Treatment Modalities

(2011) Aileen Healy et al.   ACS Chemical Neuroscience

Targeted treatments for fragile X syndrome

(2011) Elizabeth Berry-Kravis et al.   Journal of Neurodevelopmental Disorders

AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome

(2011) Josien Levenga et al.   NEUROBIOLOGY OF DISEASE

Subregion-specific dendritic spine abnormalities in the hippocampus of Fmr1 KO mice

(2011) Josien Levenga et al.   NEUROBIOLOGY OF LEARNING AND MEMORY

Which Comes First in Fragile X Syndrome, Dendritic Spine Dysgenesis or Defects in Circuit Plasticity?

(2011) Carlos Portera-Cailliau   NEUROSCIENTIST

Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

(2011) S. Jacquemont et al.   Science Translational Medicine

Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome

(2010) Tao Su et al.   PSYCHOPHARMACOLOGY

Fragile X and autism: Intertwined at the molecular level leading to targeted treatments

(2010) Randi Hagerman et al.   Molecular Autism

Incidence of Fragile X Syndrome by Newborn Screening for Methylated FMR1 DNA

(2009) Bradford Coffee et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Automated quantification of dendritic spine density and spine head diameter in medium spiny neurons of the nucleus accumbens

(2008) Haowei Shen et al.   Brain Structure & Function